盛洋投資(00174.HK)預計中期由虧轉盈逾1500萬港元
格隆匯7月30日丨盛洋投資(00174.HK)公佈,公司預期將於截至2021年6月30日止六個月錄得分屬於公司股東的未經審核中期綜合溢利不少於港幣1500萬元,上年同期虧損港幣1.27億元。
董事局認為轉虧為盈主要由於市況有所改善,尤其是中國及美國經濟漸見覆蘇。於截至2021年6月30日止六個月,集團於基金的投資表現有所改善,而於2020年同期出現虧損的主要原因是新型冠狀病毒COVID-19疫情爆發導致公司的間接非全資附屬公司(集團當時的聯營公司)Gemini-Rosemont Realty LLC於美國非核心市場的投資物業的公允值減少及作出額外撥備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.